The world of drug development is rapidly changing, driven by the dramatic evolution of technology and science. Big data and analytics now play a key role in driving decisions throughout the drug development process – influencing everything from product vision and asset valuation discussions, to site selection and study design, to launch and commercialization strategies.
IQVIA Biotech delivers clinical and commercial solutions designed specifically to help biotech companies succeed. We are inspired by you, your ambition and dedication to finding innovative ways to get treatments to patients, and the courage it takes to forge a new path forward.
IQVIA Biotech can help pave a path forward with customized, integrated solutions across the drug development and commercialization lifecycle — from designing asset plans through product trials, launch and growth. By combining advanced analytics, real world data and leading-edge technology, we help you attain success by demonstrating asset value to a wide variety of stakeholders – from investors to regulatory agencies, payers, and providers.
With decades of experience working with biotech companies, we understand the unique challenges, hurdles and opportunities you face. Our team is dedicated to removing the complexities in your way.
1700 Perimeter Park Drive
Morrisville, NC 27560
Take a closer look at funding strategies for companies launching products for the first time. Does partnering or "Going it Alone" make more sense for emerging companies? Read the findings of a 2006-2015 analysis, including implications for research companies, their potential large pharma commercialization partners, and venture capitalists.
Our RFP planning guide is a must-have for oncology sponsors. Identify key cost drivers, save time, make planning easier. IQVIA Biotech developed this guide to help emerging oncology sponsors navigate clinical outsourcing with timeline and financial considerations in mind.
Learn how IQVIA Biotech helped a biotechnology company reach critical milestones as it prepared to launch an international Phase III clinical trial for its investigational ALK inhibitor in patients with non-small cell lung cancer.
Advancements in science and technology are driving accelerated timelines and creative pathways for oncology drug development. Oncology sponsors and regulators seek new ways to efficiently move promising therapies from the clinic to approval – embracing a streamlined path that bypasses the traditional development paradigm of standalone sequential Phase I/II/III trials.
In an increasingly complex drug development and healthcare environment, it is extremely important for companies to be able to demonstrate value, even if their intention is to be acquired or to out-license their asset following proof-of-concept. Learn more about partnering solutions available to small and emerging biotech companies.
While demonstrating the value of a product is important for any organization, the pressure is more acute for small and emerging biotech companies. It’s critical to convey to investors that your drug candidate has the potential to meet the unmet needs of patients today and tomorrow. Explore 3 key components to creating a compelling value story.